Abstract:ABSTRACT Yersinia pestis has a broad host range and has caused lethal bubonic and pneumonic plague in humans. With the emergence of multiple resistant strains and the potential for biothreat use, there is an urgent need for new therapeutic strategies that can protect populations from natural or deliberate infection. Targeting F1 has been proven to be the main strategy for developing vaccines and therapeutic antibodies, but data on anti-F1 antibodies, especially in humans, are scarce. To date, three human anti-F1 monoclonal antibodies (m252, αF1Ig2, and αF1Ig8) from naive populations have been reported. Here, we constructed an antibody library from vaccinees immunized with the plague subunit vaccine IIa by phage display. The genetic basis, epitopes, and biological functions of the obtained mAbs were assessed and evaluated in plague-challenged mice. Three human mAbs, namely, F3, F19, and F23, were identified. Their biolayer responses were 0.4, 0.6, and 0.6 nm, respectively. The dissociation constants (K D ) of the F1 antigen were 1 pM, 0.165 nM, and 1 pM, respectively. Although derived from distinct Ab lineages, that is, VH3-30-D3-10-JH4 (F3&F23) and VH3-43-D6-19-JH4 (F19), these mAbs share similar binding sites in F1 with some overlap with αF1Ig8 but are distinct from αF1Ig2. Each of them provided a significant protective effect for Balb/c mice against a 100 median lethal dose (MLD) challenge of a virulent Y. pestis strain when administered at a dose of 100 μg. No synergistic or antagonistic effects were observed among them. These mAbs are novel and excellent candidates for further drug development and use in clinical practice. IMPORTANCE In this study, we identified three human monoclonal antibodies with a high affinity to F1 protein of Yersinia pestis . We discovered that they have relatively lower somatic hypermutations compared with antibodies, m252, αF1Ig2, and αF1Ig8, derived from the naive library reported previously. We also observed that these mAbs share similar binding sites in F1 with some overlapping with αF1Ig8 but distinct from that of αF1Ig2. Furthermore, each of them could provide complete protection for mice against a lethal dose of Yersinia pestis challenge. Our data provided new insights into the anti-F1 Ab repertories and their associated epitopes during vaccination in humans. The findings support the additional novel protective human anti-F1Abs for potential therapeutics against plaque.

The study on the antibody profiles in bubonic plague patients

Proteomics Investigation of Diverse Serological Patterns in COVID-19

Kinetics of Memory B Cell and Plasma Cell Responses in the Mice Immunized with Plague Vaccines

[Study on the Application and Evaluation of Methods for Gene and Antigen Detection in Plague Surveillance Program].

Dynamic Changes of Viral Load and Antibodies Level in the Patients of Severe Acute Respiratory Syndrome

Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

Dynamic Changes in IgG and IgM Antibodies As Clinical Indicators During Recovery Stage in Patients with Severe Acute Respiratory Syndrome

Dynamic Variations in the Peripheral Blood Lymphocyte Subgroups of Patients with 2009 Pandemic H1N1 Swine-Origin Influenza A Virus Infection

Evaluation of human antibodies from vaccinated volunteers for protection against Yersinia pestis infection

[Study on the Location of Membrane and Detection of Antibody in the Sera of Genus-Specific Antigen LipL41s in Patients with Leptospira Interrogans].

Single-cell Transcriptomics of Immune Cells in Lymph Nodes Reveals Their Composition and Alterations in Functional Dynamics During the Early Stages of Bubonic Plague.

Expression Levels of Major Virulence Genes in a Low-pathogenicity Isolate of Listeria monocytogenes

Secretome and Comparative Proteomics of <i>Yersinia pestis</i> Identify Two Novel E3 Ubiquitin Ligases That Contribute to Plague Virulence

Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients.

Protein Typing of Major Outer Membrane Lipoproteins from Chinese Pathogenic Leptospira Spp. and Characterization of Their Immunogenicity

[Primary Investigation on the Changing Mode of Plasma Specific IgG Antibody in SARS Patients and Their Physicians and Nurses].

Detection of the Biochemical Characters of Yersinia Pestis Isolated from Microtus Fuscus in Plague Natural Focus

Yersinia pestis versus Yersinia pseudotuberculosis: effects on host macrophages.

[Prospective Clinical Study on Serum Immunity in IgG-antibodies Positive Patients Convalescent from Severe Acute Respiratory Syndrome].

Development of Colloidal Gold Reagent for Yersinia Pestis F1 Antibody and Its Field Evaluation

[A Follow Up Study of Total IgM, IgG, Nucleoprotein and Spike Protein Antibodies Against Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS].